These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33746084)

  • 21. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.
    Kulkarni SR; Soroka CJ; Hagey LR; Boyer JL
    Hepatology; 2016 Dec; 64(6):2151-2164. PubMed ID: 27639250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
    Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
    Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PGC1α deficiency reverses cholestasis-induced liver injury via attenuating hepatic inflammation and promoting bile duct remodeling.
    Li D; Ye C; Liu P; Sun T; Qin Y; Wan X
    Acta Histochem; 2023 Dec; 125(8):152097. PubMed ID: 37813066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
    Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
    Glaser F; John C; Engel B; Höh B; Weidemann S; Dieckhoff J; Stein S; Becker N; Casar C; Schuran FA; Wieschendorf B; Preti M; Jessen F; Franke A; Carambia A; Lohse AW; Ittrich H; Herkel J; Heeren J; Schramm C; Schwinge D
    J Hepatol; 2019 Oct; 71(4):783-792. PubMed ID: 31207266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel murine model of reversible bile duct obstruction demonstrates rapid improvement of cholestatic liver injury.
    Taylor SA; Yeap XY; Wang JJ; Gromer KD; Kriegermeier A; Green RM; Zhang ZJ
    Physiol Rep; 2020 May; 8(10):e14446. PubMed ID: 32441483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-200c-3p targets SESN1 and represses the IL-6/AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis.
    Song Y; Tran M; Wang L; Shin DJ; Wu J
    Lab Invest; 2022 May; 102(5):485-493. PubMed ID: 34880414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
    Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
    JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation.
    Gehrke N; Nagel M; Straub BK; Wörns MA; Schuchmann M; Galle PR; Schattenberg JM
    Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G319-G333. PubMed ID: 29191940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nerve growth factor induced farnesoid X receptor upregulation modulates autophagy flux and protects hepatocytes in cholestatic livers.
    Tsai MS; Lee HM; Huang SC; Sun CK; Chiu TC; Chen PH; Lin YC; Hung TM; Lee PH; Kao YH
    Arch Biochem Biophys; 2020 Mar; 682():108281. PubMed ID: 32001246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury.
    Shearn CT; Anderson AL; Miller CG; Noyd RC; Devereaux MW; Balasubramaniyan N; Orlicky DJ; Schmidt EE; Sokol RJ
    Hepatol Commun; 2023 Jan; 7(1):e0020. PubMed ID: 36633484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.
    Li X; Liu R; Huang Z; Gurley EC; Wang X; Wang J; He H; Yang H; Lai G; Zhang L; Bajaj JS; White M; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2018 Aug; 68(2):599-615. PubMed ID: 29425397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholestasis downregulate hepcidin expression through inhibiting IL-6-induced phosphorylation of signal transducer and activator of transcription 3 signaling.
    Huang YH; Chuang JH; Yang YL; Huang CC; Wu CL; Chen CL
    Lab Invest; 2009 Oct; 89(10):1128-39. PubMed ID: 19652645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.
    Blokker BA; Maijo M; Echeandia M; Galduroz M; Patterson AM; Ten A; Philo M; Schungel R; Gutierrez-de Juan V; Halilbasic E; Fuchs C; Le Gall G; Milkiewicz M; Milkiewicz P; Banales JM; Rushbrook SM; Mato JM; Trauner M; Müller M; Martínez-Chantar ML; Varela-Rey M; Beraza N
    Hepatology; 2019 Feb; 69(2):699-716. PubMed ID: 30229970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-194 Up-Regulates Cholesterol 7 Alpha-Hydroxylase Expression via β-Catenin Signaling and Aggravates Cholestatic Liver Diseases.
    Chen PC; Hsu CP; Wang SY; Wu TY; Lin YJ; Chen YT; Hsu SH
    Am J Pathol; 2023 Jun; 193(6):755-768. PubMed ID: 36868469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation.
    Jang JH; Rickenbacher A; Humar B; Weber A; Raptis DA; Lehmann K; Stieger B; Moritz W; Soll C; Georgiev P; Fischer D; Laczko E; Graf R; Clavien PA
    Hepatology; 2012 Jul; 56(1):209-18. PubMed ID: 22290718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice.
    Huang YH; Yang YL; Huang FC; Tiao MM; Lin YC; Tsai MH; Wang FS
    Exp Biol Med (Maywood); 2018 Jan; 243(1):13-21. PubMed ID: 29105510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
    Kimura M; Nishikawa K; Osawa Y; Imamura J; Yamaji K; Harada K; Yatsuhashi H; Murata K; Miura K; Tanaka A; Kanto T; Kohara M; Kamisawa T; Kimura K
    Hepatol Commun; 2022 Oct; 6(10):2732-2747. PubMed ID: 35855613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
    Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
    FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of neutrophil extracellular trap components ameliorates cholestatic liver disease in Mdr2 (Abcb4) knockout mice.
    Hintermann E; Tondello C; Fuchs S; Bayer M; Pfeilschifter JM; Taubert R; Mollenhauer M; Elferink RPJO; Manns MP; Christen U
    J Autoimmun; 2024 Jun; 146():103229. PubMed ID: 38653165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.